Skip to main content

Page last checked

Comparison · sourced side by side

Survodutide vs Tirzepatide

Nobody has ever tested survodutide against tirzepatide head to head. Each one went up against a dummy treatment on its own, in different people, for different lengths of time. Their numbers come from separate experiments, so subtracting one from the other tells you nothing. Below, each record stands on its own.

Human trial FDA label

What matters first

Head-to-head evidence
No direct trial
Survodutide record
Human trial; 1 sourced dose row
Tirzepatide record
FDA label; 2 sourced dose rows

Is there a head-to-head trial?

No trial has ever compared survodutide and tirzepatide head to head. Putting separate trials side by side can make a false comparison. The trials may include different people, run for different lengths of time, and measure at different moments. The gap between their numbers is not a measured difference between the drugs.

Each result can still be read on its own. Both appear below with their own citations, but not on one shared chart.

SurvodutideHuman trial

46-week phase 2 dose-finding trial (20-week escalation + 26-week maintenance) · 387 participants · 46 weeks

  • 0.6 mg — -6.2% mean weight change
  • 2.4 mg — -12.5% mean weight change
  • 3.6 mg — -13.2% mean weight change
  • 4.8 mg — -14.9% mean weight change
  • placebo — -2.8%
The full survodutide record →
TirzepatideFDA label

Approved with a prescribing label; its dosing schedule and reaction profile are label-sourced and shown in the table below.

The full tirzepatide record →

Side by side

Every row is read from the two records, and every clinical figure carries its own citation. Where a value does not exist, the row says so instead of guessing one.

Survodutide and Tirzepatide side by side: drug class, brand names, FDA approval, strongest source, dosing, half-life, boxed warning, reported reactions and typical vial sizes
PropertySurvodutideTirzepatide
Drug classGlucagon/GLP-1 dual receptor agonist (investigational)GIP/GLP-1 dual receptor agonist
Brand namesNone — no approved productZepbound, Mounjaro
FDA approvalNot approved — investigationalApproved
Strongest sourceHuman trialFDA label
Dosing0.6–4.8 mg once weekly (phase 2 arms: 0.6, 2.4, 3.6 or 4.8 mg, reached by up to 20 weeks of escalation)5–15 mg once weekly (5, 10, or 15 mg)
Half-lifeNot recorded≈ 5 days
Boxed warningNone on recordRisk of thyroid C-cell tumors
Reactions on record415
Typical vial sizes5 mg · 10 mg5 mg · 10 mg · 15 mg · 30 mg · 60 mg

Every clinical value above is cited in the Sources list. Reference information, not a recommendation.

4Comparison detailsMechanism, side effects, regulatory context, and source records

How they work differently

Survodutide is a glucagon/glp-1 dual receptor agonist. Tirzepatide is a gip/glp-1 dual receptor agonist. They switch on different signals in the body. That can change both benefits and side effects. Sharing one target does not make two drugs interchangeable.

More targets do not guarantee a better result. They change both the effect and the side-effect pattern. A clinician weighs those tradeoffs for each person.

Side effects compared

Side effects below come from each compound’s own page, grouped by whether both records list them. A side effect on one list only means the other record does not carry it — not that it never happens.

On both records
  • Nausea
  • Vomiting
Recorded for Survodutide only
  • Stomach and gut events overall (nausea, vomiting, constipation)
  • any side effect
Recorded for Tirzepatide only
  • Diarrhea
  • Constipation
  • Abdominal pain
  • Dyspepsia (indigestion)
  • Decreased appetite
  • reactions where injected
  • Fatigue
  • Acute pancreatitis
  • Gallbladder disease (cholelithiasis)
  • Hypoglycemia (with insulin or a sulfonylurea)
  • Acute kidney injury (from dehydration)
  • Diabetic retinopathy complications
  • Severe hypersensitivity reactions
Full survodutide side-effect record

Frequencies, serious reactions and the source for each.

Full tirzepatide side-effect record

Frequencies, serious reactions and the source for each.

Regulatory status compared

Survodutide

FDA has not approved survodutide, also called BI 456906.

Phase 3 SYNCHRONIZE trials study obesity. A separate phase 2 program studies MASH, a form of liver disease. No dosing label exists, and any product sold today is unapproved.

The doses here describe study groups, not advice.

Tirzepatide

FDA-approved as branded pens.

Compounded tirzepatide now faces tight limits. FDA declared the shortage over in late 2024. It has proposed dropping tirzepatide from the 503B bulks list.

That leaves one narrow lane: 503A compounding for a named patient with a documented clinical need.

The full regulatory tracker →

Keep reading

A comparison is a summary of two records. These are the pages themselves, plus the tools and schedules the rows above are read from.

What the sources say about survodutide, beyond survodutide vs tirzepatide

4 sourced survodutide reactions, on its own page, separate from survodutide vs tirzepatide.

Tirzepatide on its own page, outside survodutide vs tirzepatide

An approved tirzepatide label exists — beyond survodutide vs tirzepatide.

Work out a tirzepatide draw, one side of survodutide vs tirzepatide

Tirzepatide vial sizes: 5 mg, 10 mg, 15 mg, 30 mg and 60 mg. These do not come from survodutide vs tirzepatide.

The survodutide calculator behind survodutide vs tirzepatide

The survodutide vial presets are 1 mL and 2 mL of water. They belong to this tool, not to the survodutide vs tirzepatide page.

The survodutide schedule that survodutide vs tirzepatide summarizes

The whole survodutide trial program, in full past survodutide vs tirzepatide.

Tirzepatide dosing in full, beyond survodutide vs tirzepatide

Tirzepatide has an approved label. This is separate from survodutide vs tirzepatide.

Mixing math for any peptide, with survodutide vs tirzepatide as one example

Concentration, units per draw and draws per vial, including Survodutide vs tirzepatide

Where survodutide vs tirzepatide sits among the comparisons

Molecule and product comparisons stay separate, including Survodutide vs tirzepatide

The dated regulatory page behind survodutide vs tirzepatide

Every entry cites its source. It comes from the Federal Register or fda.gov, with survodutide vs tirzepatide as context

How both pages in survodutide vs tirzepatide were source-checked

How an FDA label differs from a human trial or a claim with no human data, with survodutide vs tirzepatide as one example

Common questions

Which is more effective, survodutide or tirzepatide?

Nobody knows, because nobody has tested them against each other. Each was tested separately against a dummy treatment, and those two results cannot be subtracted to give a difference.

Can these two be compared using their separate trial results?

Not reliably. Separate trials can include different people, run for different lengths of time, and measure different things. Only a head-to-head trial measures the difference.

Are the side-effect profiles the same?

They overlap a lot — 2 side effects appear on both records, mostly stomach-related. The lists also differ. Evidence from an approved label is stronger than an early trial report.

Is either one approved by the FDA?

Tirzepatide is FDA-approved and has a prescribing label. Survodutide is still experimental, has no approved label, and anything sold today is unapproved.

Does a newer compound mean a better one?

No. A newer drug often has less evidence, a shorter safety record, and no approved label. The strength of the evidence above is more useful than age alone.

Can someone switch between them?

A clinician decides that based on the reason for treatment, the current dose, and how the first drug felt. A prescribing clinician should advise on any treatment change.

Questions readers ask

Is anything better than tirzepatide?

Nothing has beaten it in a head-to-head trial. The only one run so far is SURMOUNT-5, where it came out ahead of semaglutide, 20.2% against 13.7% over 72 weeks.

Survodutide’s own numbers come from a separate phase 2 trial with no tirzepatide arm, so the two cannot be ranked against each other.

When will survodutide be approved?

There is no date, and nobody can supply one. Survodutide is still in trials — the phase 3 SYNCHRONIZE program in obesity, with a separate phase 2 program in liver disease.

No prescribing label exists for it, so anything sold today under that name has no FDA approval behind it.

How effective is survodutide for weight loss?

Its 46-week phase 2 trial in 387 people reported average weight change of −6.2% to −14.9% across four arms. Placebo was −2.8%.

That is a dose-finding trial rather than a phase 3 result, and it was not compared against another drug.

Is tirzepatide going to be discontinued?

Nothing in the FDA records this site reads says so. Both tirzepatide products are on sale and both labels are current.

The notice people run into belongs to a different drug. Novo Nordisk has told FDA it is stopping all three Rybelsus tablet strengths, which are semaglutide.

2primary sources, each with the day we read it — open the documents used on this page